Skip to content
2000
image of Drug Delivery Strategies for the Management of Attention-deficit/ Hyperactivity Disorder (ADHD): A Case of Differentiated Product Development of Methylphenidate

Abstract

ADHD is a common condition that affects many kids in the United States, about 2 to 18 percent of children between 6 and 17 years old. ADHD manifests as hyperactivity, impulsivity, and inattention, impacting various aspects of life. Effective management involves a combination of psychostimulant medication, such as methylphenidate, and behavioral therapy. Modified-release formulations, including chewable tablets, transdermal patches, and osmotic-controlled release tablets, offer improved treatment adherence and overall quality of life. Understanding the pathophysiology involves neuroimaging studies that reveal alterations in brain regions rich in dopamine receptors. Methylphenidate, a common ADHD medication, works by inhibiting dopamine reuptake, thereby increasing extracellular dopamine levels. Different drug delivery systems, such as extended-release chewable tablets, transdermal patches, and OROS formulations, provide diverse options for individual needs. The advent of innovative formulations like methylphenidate hydrochloride extended-release oral suspension (Quillivant ER) and methylphenidate hydrochloride multilayer extended-release capsules (Aptensio XR) addresses challenges in pediatric medication administration. Recent additions like the orally disintegrating tablet (Cotempla X-ODT) offer convenience and flexibility. Understanding the pharmacokinetics, pharmacodynamics, and benefits of these formulations enhances the ability to tailor ADHD treatment to individual patient needs.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/raddf/10.2174/0126673878346123250515065256
2025-05-23
2025-11-17

  • From This Site

    /content/journals/raddf/10.2174/0126673878346123250515065256
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Berger I. Diagnosis of attention deficit hyperactivity disorder: Much ado about something. Isr Med Assoc J 2011 13 9 571 574 21991721
    [Google Scholar]
  2. Childress A.C. Berry S.A. Pharmacotherapy of attention-deficit hyperactivity disorder in adolescents. Drugs 2012 72 3 309 325 10.2165/11599580‑000000000‑00000 22316347
    [Google Scholar]
  3. Bone H.G. Chapurlat R. Brandi M.L. Brown J.P. Czerwiński E. Krieg M.A. Mellström D. Radominski S.C. Reginster J.Y. Resch H. Ivorra J.A.R. Roux C. Vittinghoff E. Daizadeh N.S. Wang A. Bradley M.N. Franchimont N. Geller M.L. Wagman R.B. Cummings S.R. Papapoulos S. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: Results from the FREEDOM extension. J. Clin. Endocrinol. Metab. 2013 98 11 4483 4492 10.1210/jc.2013‑1597 23979955
    [Google Scholar]
  4. Klassen A.F. Miller A. Fine S. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder. Pediatrics 2004 114 5 e541 e547 10.1542/peds.2004‑0844 15520087
    [Google Scholar]
  5. Barkley R.A. Global issues related to the impact of untreated attention-deficit/hyperactivity disorder from childhood to young adulthood. Postgrad. Med. 2008 120 3 48 59 10.3810/pgm.2008.09.1907 18824825
    [Google Scholar]
  6. Post R.E. Kurlansik S.L. Diagnosis and management of adult attention-deficit/hyperactivity disorder. Am Fam Physician 2012 85 9 890 896 22612184
    [Google Scholar]
  7. Seixas M. Weiss M. Müller U. Systematic review of national and international guidelines on attention-deficit hyperactivity disorder. J. Psychopharmacol. 2012 26 6 753 765 10.1177/0269881111412095 21948938
    [Google Scholar]
  8. Power C. Freeman N.C. Costello S. ADHD assessment recommendations for children in practice guidelines: A systematic review. Psych 2022 4 4 882 896 10.3390/psych4040065
    [Google Scholar]
  9. Wolraich M. Brown L. Brown R.T. DuPaul G. Earls M. Feldman H.M. Ganiats T.G. Kaplanek B. Meyer B. Perrin J. Pierce K. Reiff M. Stein M.T. Visser S. ADHD: Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 2011 128 5 1007 1022 10.1542/peds.2011‑2654 22003063
    [Google Scholar]
  10. Steele M Weiss M Swanson J Wang J Prinzo RS Binder CE. A A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Can. J. Clin. Pharmacol. 2006 13 1 e50 62 16456216
    [Google Scholar]
  11. Sobanski E. Döpfner M. Ose C. Fischer R. A non-interventional study of extended-release methylphenidate in the routine treatment of adolescents with ADHD: Effectiveness, safety and adherence to treatment. Atten. Defic. Hyperact. Disord. 2013 5 4 387 395 10.1007/s12402‑013‑0113‑y 23794192
    [Google Scholar]
  12. Rothenberger A Becker A Breuer D Döpfner M An observational study of once-daily modified-release methylphenidate in ADHD: Quality of life, satisfaction with treatment and adherence. Eur. Child Adolesc. Psychiatry 2011 20 Suppl 2 S257 S265 10.1007/s00787‑011‑0203‑3 21901416
    [Google Scholar]
  13. Briars L. Todd T. A review of pharmacological management of attention-deficit/hyperactivity disorder. J. Pediatr. Pharmacol. Ther. 2016 21 3 192 206 10.5863/1551‑6776‑21.3.192 27453697
    [Google Scholar]
  14. Hauck T.S. Lau C. Wing L.L.F. Kurdyak P. Tu K. ADHD treatment in primary care: Demographic factors, medication trends, and treatment predictors. Can. J. Psychiatry 2017 62 6 393 402 10.1177/0706743716689055 28103079
    [Google Scholar]
  15. Smoller J.W. Andreassen O.A. Edenberg H.J. Faraone S.V. Glatt S.J. Kendler K.S. Psychiatric genetics and the structure of psychopathology. Mol. Psychiatry 2019 24 3 409 420 10.1038/s41380‑017‑0010‑4 29317742
    [Google Scholar]
  16. Coghill D. Sonuga-Barke E.J.S. Annual Research Review: Categories versus dimensions in the classification and conceptualisation of child and adolescent mental disorders – Implications of recent empirical study. J. Child Psychol. Psychiatry 2012 53 5 469 489 10.1111/j.1469‑7610.2011.02511.x 22288576
    [Google Scholar]
  17. Scheffler R.M. Hinshaw S.P. Modrek S. Levine P. The global market for ADHD medications. Health Aff. 2007 26 2 450 457 10.1377/hlthaff.26.2.450 17339673
    [Google Scholar]
  18. Pliszka S.R. Crismon M.L. Hughes C.W. Corners C.K. Emslie G.J. Jensen P.S. McCRACKEN J.T. Swanson J.M. Lopez M. The Texas children’s medication algorithm project: Revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 2006 45 6 642 657 10.1097/01.chi.0000215326.51175.eb 16721314
    [Google Scholar]
  19. Chang Z. Ghirardi L. Quinn P.D. Asherson P. D’Onofrio B.M. Larsson H. Risks and benefits of attention-deficit/hyperactivity disorder medication on behavioral and neuropsychiatric outcomes: A qualitative review of pharmacoepidemiology studies using linked prescription databases. Biol. Psychiatry 2019 86 5 335 343 10.1016/j.biopsych.2019.04.009 31155139
    [Google Scholar]
  20. Molina B.S.G. Hinshaw S.P. Swanson J.M. Arnold L.E. Vitiello B. Jensen P.S. Epstein J.N. Hoza B. Hechtman L. Abikoff H.B. Elliott G.R. Greenhill L.L. Newcorn J.H. Wells K.C. Wigal T. Gibbons R.D. Hur K. Houck P.R. The MTA at 8 years: Prospective follow-up of children treated for combined-type ADHD in a multisite study. J. Am. Acad. Child Adolesc. Psychiatry 2009 48 5 484 500 10.1097/CHI.0b013e31819c23d0 19318991
    [Google Scholar]
  21. Wolraich M.L. The new attention deficit hyperactivity disorder clinical practice guidelines published by the American academy of pediatrics. J. Dev. Behav. Pediatr. 2012 33 1 76 77 10.1097/DBP.0b013e318241eadf 22218017
    [Google Scholar]
  22. Swanson J. Castellanos F.X. Murias M. LaHoste G. Kennedy J. Cognitive neuroscience of attention deficit hyperactivity disorder and hyperkinetic disorder. Curr. Opin. Neurobiol. 1998 8 2 263 271 10.1016/S0959‑4388(98)80150‑5 9635212
    [Google Scholar]
  23. Lou H.C. Henriksen L. Bruhn P. Focal cerebral hypoperfusion in children with dysphasia and/or attention deficit disorder. Arch. Neurol. 1984 41 8 825 829 10.1001/archneur.1984.04050190031010 6331818
    [Google Scholar]
  24. Vaidya C.J. Austin G. Kirkorian G. Ridlehuber H.W. Desmond J.E. Glover G.H. Gabrieli J.D.E. Selective effects of methylphenidate in attention deficit hyperactivity disorder: A functional magnetic resonance study. Proc. Natl. Acad. Sci. USA 1998 95 24 14494 14499 10.1073/pnas.95.24.14494 9826728
    [Google Scholar]
  25. Lou H.C. Henriksen L. Bruhn P. Børner H. Nielsen J.B. Striatal dysfunction in attention deficit and hyperkinetic disorder. Arch. Neurol. 1989 46 1 48 52 10.1001/archneur.1989.00520370050018 2783366
    [Google Scholar]
  26. Zametkin A.J. Liebenauer L.L. Fitzgerald G.A. King A.C. Minkunas D.V. Herscovitch P. Yamada E.M. Cohen R.M. Brain metabolism in teenagers with attention-deficit hyperactivity disorder. Arch. Gen. Psychiatry 1993 50 5 333 340 10.1001/archpsyc.1993.01820170011002 8489322
    [Google Scholar]
  27. Ernst M. Zametkin A.J. Matochik J.A. Pascualvaca D. Jons P.H. Cohen R.M. High midbrain [18F]DOPA accumulation in children with attention deficit hyperactivity disorder. Am. J. Psychiatry 1999 156 8 1209 1215 10.1176/ajp.156.8.1209 10450262
    [Google Scholar]
  28. Swanson J.M. Flodman P. Kennedy J. Spence M.A. Moyzis R. Schuck S. Murias M. Moriarity J. Barr C. Smith M. Posner M. Dopamine genes and ADHD. Neurosci. Biobehav. Rev. 2000 24 1 21 25 10.1016/S0149‑7634(99)00062‑7 10654656
    [Google Scholar]
  29. Levy F. The dopamine theory of attention deficit hyperactivity disorder (ADHD). Aust. N. Z. J. Psychiatry 1991 25 2 277 283 10.3109/00048679109077746 1652243
    [Google Scholar]
  30. Pliszka S.R. McCracken J.T. Maas J.W. Catecholamines in attention-deficit hyperactivity disorder: Current perspectives. J. Am. Acad. Child Adolesc. Psychiatry 1996 35 3 264 272 10.1097/00004583‑199603000‑00006 8714313
    [Google Scholar]
  31. Biederman J. Milberger S. Faraone S.V. Kiely K. Guite J. Mick E. Ablon S. Warburton R. Reed E. Family-environment risk factors for attention-deficit hyperactivity disorder. A test of Rutter’s indicators of adversity. Arch. Gen. Psychiatry 1995 52 6 464 470 10.1001/archpsyc.1995.03950180050007 7771916
    [Google Scholar]
  32. Volkow N.D. Wang G.J. Fowler J.S. Ding Y.S. Imaging the effects of methylphenidate on brain dopamine: New model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol. Psychiatry 2005 57 11 1410 1415 10.1016/j.biopsych.2004.11.006 15950015
    [Google Scholar]
  33. Faraone S.V. Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur. Child Adolesc. Psychiatry 2010 19 4 353 364 10.1007/s00787‑009‑0054‑3 19763664
    [Google Scholar]
  34. Greenhill L. Kollins S. Abikoff H. McCracken J. Riddle M. Swanson J. McGough J. Wigal S. Wigal T. Vitiello B. Skrobala A. Posner K. Ghuman J. Cunningham C. Davies M. Chuang S. Cooper Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J. Am. Acad. Child Adolesc. Psychiatry 2006 45 11 1284 1293 10.1097/01.chi.0000235077.32661.61 17023867
    [Google Scholar]
  35. Jaeschke R.R. Sujkowska E. Sowa-Kućma M. Methylphenidate for attention-deficit/hyperactivity disorder in adults: A narrative review. Psychopharmacology (Berl.) 2021 238 10 2667 2691 10.1007/s00213‑021‑05946‑0 34436651
    [Google Scholar]
  36. Faraone S.V. The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neurosci. Biobehav. Rev. 2018 87 255 270 10.1016/j.neubiorev.2018.02.001 29428394
    [Google Scholar]
  37. Brahmankar D.M. Jaiswal S.B. Biopharmaceutics and Pharmacokinetics: A Treatise. Vallabh Prakashan 2009
    [Google Scholar]
  38. Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association Washington, DC 4th ed 1994
    [Google Scholar]
  39. Barkley R.A. Attention-deficit hyperactivity disorder. Guilford Press New York 2003
    [Google Scholar]
  40. Gittelman-Klein R. Review of clinical psychopharmacological treatment of hyperkinesis. Progress in psychiatric drug treatment. New York Brunner/Mazel 1975 661 674
    [Google Scholar]
  41. Werry J.S. Drugs, learning and cognitive function in children--An update. J. Child Psychol. Psychiatry 1988 29 2 129 141 10.1111/j.1469‑7610.1988.tb00698.x 2897374
    [Google Scholar]
  42. Gualtieri C.T. Kanoy R. Hawk B. Koriath U. Schroeder S. Youngblood W. Breese G.R. Prange A.J. Jr Growth hormone and prolactin secretion in adults and hyperactive children: Relation to methylphenidate serum levels. Psychoneuroendocrinology 1981 6 4 331 339 10.1016/0306‑4530(81)90018‑4 7323251
    [Google Scholar]
  43. Firestone P. Factors associated with children’s adherence to stimulant medication. Am. J. Orthopsychiatry 1982 52 3 447 457 10.1111/j.1939‑0025.1982.tb01431.x 7114173
    [Google Scholar]
  44. Brown R.T. Borden K.A. Clingerman S.R. Adherence to methylphenidate therapy in a pediatric population: A preliminary investigation. Psychopharmacol. Bull. 1985 21 1 28 36 3983335
    [Google Scholar]
  45. Swanson J.M. Volkow N.D. Psychopharmacology: Concepts and opinions about the use of stimulant medications. J. Child Psychol. Psychiatry 2009 50 1-2 180 193 10.1111/j.1469‑7610.2008.02062.x 19220601
    [Google Scholar]
  46. Greenhill L.L. Pliszka S. Dulcan M.K. Bernet W. Arnold V. Beitchman J. Benson R.S. Bukstein O. Kinlan J. McClellan J. Rue D. Shaw J.A. Stock S. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J. Am. Acad. Child Adolesc. Psychiatry 2002 41 2 Suppl. 26S 49S 10.1097/00004583‑200202001‑00003 11833633
    [Google Scholar]
  47. Colombo P. Bettini R. Santi P. Peppas N.A. Swellable matrices for controlled drug delivery: Gel-layer behaviour, mechanisms and optimal performance. Pharm. Sci. Technol. Today 2000 3 6 198 204 10.1016/S1461‑5347(00)00269‑8 10840390
    [Google Scholar]
  48. Moen M.D. Keam S.J. Dexmethylphenidate extended release: A review of its use in the treatment of attention-deficit hyperactivity disorder. CNS Drugs 2009 23 12 1057 1083 10.2165/11201140‑000000000‑00000 19958043
    [Google Scholar]
  49. Childress A.C. Komolova M. Sallee F.R. An update on the pharmacokinetic considerations in the treatment of ADHD with long-acting methylphenidate and amphetamine formulations. Expert Opin. Drug Metab. Toxicol. 2019 15 11 937 974 10.1080/17425255.2019.1675636 31581854
    [Google Scholar]
  50. Cosentyx. 2011 Available from: https://www.novartis.com/us-en/sites/novartis_us/files/cosentyx.pdf
  51. Lyseng-Williamson K.A. Keating G.M. Extended-release methylphenidate (Ritalin LA). Drugs 2002 62 15 2251 2259 10.2165/00003495‑200262150‑00012 12381228
    [Google Scholar]
  52. Lee L. Kepple J. Wang Y. Freestone S. Bakhtiar R. Wang Y. Hossain M. Bioavailability of modified‐release methylphenidate: Influence of high‐fat breakfast when administered intact and when capsule content sprinkled on applesauce. Biopharm. Drug Dispos. 2003 24 6 233 243 10.1002/bdd.358 12973820
    [Google Scholar]
  53. Srivastava RC Nagappa AN Surface activity in drug action. Elsevier Amsterdam, The Netherlands 2005
    [Google Scholar]
  54. Vyas SP Khar RK Controlled drug delivery concepts and advances. vallabh prakashan Delhi, India 2002
    [Google Scholar]
  55. Spencer T. Biederman J. Wilens T. Harding M. O’Donnell D. Griffin S. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J. Am. Acad. Child Adolesc. Psychiatry 1996 35 4 409 432 10.1097/00004583‑199604000‑00008 8919704
    [Google Scholar]
  56. Findling R.L. Dogin J.W. Psychopharmacology of ADHD: Children and adolescents. J. Clin. Psychiatry 1998 59 7 Suppl. 7 42 49 9680052
    [Google Scholar]
  57. Silberstein S.D. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review): Report of the quality standards subcommittee of the American academy of neurology. Neurology 2000 55 6 754 762 10.1212/WNL.55.6.754 10993991
    [Google Scholar]
  58. Pelham W.E. Gnagy E.M. Burrows-Maclean L. Williams A. Fabiano G.A. Morrisey S.M. Chronis A.M. Forehand G.L. Nguyen C.A. Hoffman M.T. Lock T.M. Fielbelkorn K. Coles E.K. Panahon C.J. Steiner R.L. Meichenbaum D.L. Onyango A.N. Morse G.D. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 2001 107 6 e105 10.1542/peds.107.6.e105 11389303
    [Google Scholar]
  59. Pierce D. Katic A. Buckwalter M. Webster K. Single- and multiple-dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic-release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder. J. Clin. Psychopharmacol. 2010 30 5 554 564 10.1097/JCP.0b013e3181f0c2f6 20814325
    [Google Scholar]
  60. Coghill D. Banaschewski T. Zuddas A. Pelaz A. Gagliano A. Doepfner M. Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: A systematic review of head-to-head studies. BMC Psychiatry 2013 13 1 237 10.1186/1471‑244X‑13‑237 24074240
    [Google Scholar]
  61. Prausnitz M.R. Langer R. Transdermal drug delivery. Nat. Biotechnol. 2008 26 11 1261 1268 10.1038/nbt.1504 18997767
    [Google Scholar]
  62. Findling R.L. Bukstein O.G. Melmed R.D. López F.A. Sallee F.R. Arnold L.E. Pratt R.D. A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder. J. Clin. Psychiatry 2008 69 1 149 159 10.4088/JCP.v69n0120 18312050
    [Google Scholar]
  63. Robb A.S. Findling R.L. Childress A.C. Berry S.A. Belden H.W. Wigal S.B. Efficacy, safety, and tolerability of a novel methylphenidate extended-release oral suspension (MEROS) in ADHD. J. Atten. Disord. 2017 21 14 1180 1191 10.1177/1087054714533191 24874348
    [Google Scholar]
  64. Wigal S.B. Childress A.C. Belden H.W. Berry S.A. NWP06, an extended-release oral suspension of methylphenidate, improved attention-deficit/hyperactivity disorder symptoms compared with placebo in a laboratory classroom study. J. Child Adolesc. Psychopharmacol. 2013 23 1 3 10 10.1089/cap.2012.0073 23289899
    [Google Scholar]
  65. Herman B.K. King T.R. Kando J.C. Pardo A. 89 A novel, modified-release drug delivery technology containing amphetamine-ion exchange complexes. CNS Spectr. 2019 24 1 220 10.1017/S1092852919000671
    [Google Scholar]
  66. Mattingly G.W. Wilson J. Rostain A.L. A clinician’s guide to ADHD treatment options. Postgrad. Med. 2017 129 7 657 666 10.1080/00325481.2017.1354648 28762862
    [Google Scholar]
  67. Swarbick J. Boylan J.C. Encyclopedia of Pharmaceutical Technology. Marcel Dekker, Inc. New York 229 264
    [Google Scholar]
  68. Davies N.M. Feddah M.R. A novel method for assessing dissolution of aerosol inhaler products. Int. J. Pharm. 2003 255 1-2 175 187 10.1016/S0378‑5173(03)00091‑7 12672613
    [Google Scholar]
  69. Childress A.C. Sallee F.R. Berry S.A. Single-dose pharmacokinetics of NWP06, an extended-release methylphenidate suspension, in children and adolescents with ADHD. Postgrad. Med. 2011 123 5 80 88 10.3810/pgm.2011.09.2462 21904089
    [Google Scholar]
  70. Pandey S. Uttam Singh U.P. Manufacturing challenges in pharmaceutical industry. J. Pharm. Sci. 2020 109 6 2062 2071
    [Google Scholar]
  71. Davis S.S. The design and evaluation of controlled release systems for the gastrointestinal tract. J. Control. Release 1985 2 27 38 10.1016/0168‑3659(85)90030‑6
    [Google Scholar]
  72. Reilly J.S. Cook S.P. Stool D. Rider G. Prevention and management of aerodigestive foreign body injuries in childhood. Pediatr. Clin. North Am. 1996 43 6 1403 1411 10.1016/S0031‑3955(05)70525‑3 8973519
    [Google Scholar]
  73. Park K Wood RW Robinson JR Oral controlled release systems. Medical Applications of Controlled Release CRC Press Boca Raton, FL 2019 159 202 10.1201/9780429276651‑6
    [Google Scholar]
  74. Siepmann J. Siepmann F. Mathematical modeling of drug delivery. Int. J. Pharm. 2008 364 2 328 343 10.1016/j.ijpharm.2008.09.004 18822362
    [Google Scholar]
  75. Abbas R. Palumbo D. Walters F. Belden H. Berry S.A. Single-dose pharmacokinetic properties and relative bioavailability of a novel methylphenidate extended-release chewable tablet compared with immediate-release methylphenidate chewable tablet. Clin. Ther. 2016 38 5 1151 1157 10.1016/j.clinthera.2016.02.026 27021606
    [Google Scholar]
  76. Thombre A.G. Design and development of oral controlled-release drug delivery systems for improved therapy. Adv. Drug Deliv. Rev. 2005 57 10 1569 1583
    [Google Scholar]
  77. Adjei A. Teuscher N.S. Kupper R.J. Chang W.W. Greenhill L. Newcorn J.H. Connor D.F. Wigal S. Single-dose pharmacokinetics of methylphenidate extended-release multiple layer beads administered as intact capsule or sprinkles versus methylphenidate immediate-release tablets (Ritalin(®)) in healthy adult volunteers. J. Child Adolesc. Psychopharmacol. 2014 24 10 570 578 10.1089/cap.2013.0135 25514542
    [Google Scholar]
  78. Theeuwes F. Elementary osmotic pump. J. Pharm. Sci. 1975 64 12 1987 1991 10.1002/jps.2600641218 1510
    [Google Scholar]
  79. Childress A. Sallee F.R. The use of methylphenidate hydrochloride extended-release oral suspension for the treatment of ADHD. Expert Rev. Neurother. 2013 13 9 979 988 10.1586/14737175.2013.833002 24053342
    [Google Scholar]
  80. Fife D. Cepeda M.S. Baseman A. Richards H. Hu P. Starr H.L. Sena A.G. Medication changes after switching from CONCERTA® brand methylphenidate HCl to a generic long-acting formulation: A retrospective database study. PLoS One 2018 13 2 e0193453 10.1371/journal.pone.0193453 29489906
    [Google Scholar]
  81. Patrick K.S. González M.A. Straughn A.B. Markowitz J.S. New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder. Expert Opin. Drug Deliv. 2005 2 1 121 143 10.1517/17425247.2.1.121 16296740
    [Google Scholar]
  82. Wolraich M.L. Doffing M.A. Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate. CNS Drugs 2004 18 4 243 250 10.2165/00023210‑200418040‑00004 15015904
    [Google Scholar]
  83. Modi N.B. Wang B. Noveck R.J. Gupta S.K. Dose-proportional and stereospecific pharmacokinetics of methylphenidate delivered using an osmotic, controlled-release oral delivery system. J. Clin. Pharmacol. 2000 40 10 1141 1149 10.1177/009127000004001008 11028253
    [Google Scholar]
  84. Modi N.B. Wang B. Hu W.T. Gupta S.K. Effect of food on the pharmacokinetics of osmotic controlled-release methylphenidate HCl in healthy subjects. Biopharm. Drug Dispos. 2000 21 1 23 31 10.1002/1099‑081X(200001)21:1<23::AID‑BDD212>3.0.CO;2‑V 11038435
    [Google Scholar]
  85. Center for drug evaluation and research: Concerta clinical pharmacology and biopharmaceutics review: Application number 21-121. 2000 Available from: https:// www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-121_ Concerta_biopharmr.pdf
  86. Modi N.B. Lindemulder B. Gupta S.K. Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation. J. Clin. Pharmacol. 2000 40 4 379 388 10.1177/00912700022009080 10761165
    [Google Scholar]
  87. Banga A.K. Therapeutic Peptides and Proteins. CRC Press 2005 10.1201/9781420039832
    [Google Scholar]
  88. Hussain A. Ahsan F. The gastrointestinal transit of non-disintegrating and disintegrating tablets in humans. Int. J. Pharm. 2005 293 1-2 57 64 15847991
    [Google Scholar]
  89. Ranmal S.R. O’Brien F. Lopez F. Ruiz F. Orlu M. Tuleu C. Walsh J. Liu F. Methodologies for assessing the acceptability of oral formulations among children and older adults: A systematic review. Drug Discov. Today 2018 23 4 830 847 10.1016/j.drudis.2018.01.038 29371123
    [Google Scholar]
/content/journals/raddf/10.2174/0126673878346123250515065256
Loading
Drug Delivery Strategies for the Management of Attention-deficit/ Hyperactivity Disorder (ADHD): A Case of Differentiated Product Development of Methylphenidate
Bentham Science Publishers ; https://doi.org/10.2174/0126673878346123250515065256
/content/journals/raddf/10.2174/0126673878346123250515065256
/content/journals/raddf/10.2174/0126673878346123250515065256
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: formulation development ; drug delivery ; differentiated product development ; attention-deficit/hyperactivity disorder ; sustained release ; Methylphenidate

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test